BlackRock Group’s Sage Therapeutics SAGE Stock Holding History

BlackRock Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.31M	Buy	103,956 +8,889	+9%	+$419K	﹤0.01%	1159
2016 Q3	$4.38M	Buy	95,067 +31,517	+50%	+$1.28M	﹤0.01%	1169
2016 Q2	$1.92M	Buy	63,550 +56,642	+820%	+$1.89M	﹤0.01%	1581
2016 Q1	$222K	Buy	6,908 +2,875	+71%	+$101K	﹤0.01%	2537
2015 Q4	$235K	Sell	4,033 -104	-3%	-$5.15K	﹤0.01%	2473
2015 Q3	$175K	Buy	4,137 +830	+25%	+$51.1K	﹤0.01%	2565
2015 Q2	$241K	Buy	+3,307	New	+$213K	﹤0.01%	2527
2015 Q1	–	Sell	-18,562	Closed	-$679K	–	2880
2014 Q4	$679K	Buy	18,562 +300	+2%	+$11.2K	﹤0.01%	2104
2014 Q3	$576K	Buy	+18,262	New	+$529K	﹤0.01%	2107

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BlackRock Group's SAGE Position: Q4 2016 in Review

BlackRock Group increased its Sage Therapeutics (SAGE) stake by 9.4% in Q4 2016, buying an estimated $419K and bringing the position to 103,956 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1159.

BlackRock Group first reported a position in SAGE in Q3 2014 and has held it in 9 quarters since. 166 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

BlackRock Group held 103,956 shares of Sage Therapeutics worth $5.31M as of Q4 2016.
BlackRock Group bought 8,889 Sage Therapeutics shares in Q4 2016, an estimated $419K.
Sage Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1159 holding.
BlackRock Group first reported a position in Sage Therapeutics in Q3 2014 and has held it in 9 quarters since.
166 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.